Neuroscience experts advising the Food and Drug Administration found that a study didn’t provide sufficient evidence that Amylyx Pharmaceuticals Inc.’s experimental amyotrophic lateral sclerosis drug works.
Their 6-to-4 vote on Wednesday sets up a new test for the FDA as it considers approving the latest experimental drug promising to slow the march of the debilitating neurodegenerative disease.
To Read the Full Story
This post first appeared on wsj.com